Evidence map›Paper›PMID 41864973›Full record

ArticleItalian journal of pediatrics2026

Exploratory study of plasma GFAP and GAD65-Ab levels in children with ADHD.

Rui-Liang Li, Yu-Dong Shan, Peng Lu, Ting-Ting Liu, Zhi-Fang Yu, Ge-Ge Lv, Na-Na Liu, Wei Zhang, Jing-Yu Zhang, Wei-Juan Gao and 2 more

Abstract read
In one paragraph

Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rui-Liang Li *Department of Hyperbaric Oxygen Medicine, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China.
Yu-Dong Shan *Hebei Province Key Laboratory of Integrated Traditional and Western Medicine in Neurological Rehabilitation, Cangzhou, China.
Peng LuGraduate School, Chengde Medical University, Chengde, China.
Ting-Ting LiuDepartment of Pediatrics, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China.
Zhi-Fang YuAnesthesia and Trauma Research Unit, Department of Anesthesiology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China.
Ge-Ge LvDepartment of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Na-Na LiuDepartment of Pediatrics, Cangzhou Central Hospital, Cangzhou, China.
Wei ZhangDepartment of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jing-Yu ZhangDepartment of Clinicallaboratory, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China.
Wei-Juan GaoHebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China.
Li-Min ZhangAnesthesia and Trauma Research Unit, Department of Anesthesiology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China. azai2010@126.com.
Hui-Tao MiaoDepartment of Anesthesiology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Cangzhou, China. m2418513532@163.com.ORCID http://orcid.org/0000-0001-5550-3885

Funding

Natural Science Foundation of Hebei Province H2024110009
6 · The paper itself

Abstract

backgroundAttention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children of school age. In mice with ADHD, glial fibrillary acidic protein (GFAP) levels were significantly higher, whereas glutamic acid decarboxylase 65 (GAD65) levels were lower. The goal of this study is to look at the potential function of GFAP and GAD65 antibodies (GAD65-Ab) in mice and children with ADHD by assessing GFAP and GAD65-Ab levels in the blood.

methodsAn ADHD model was established in pregnant mice with 15 mg/kg of S-ketamine administration using intraperitoneal injection for 5 days from G14 to G18. Children were enrolled if they met in ADHD Rating Scale (ARS) in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for ADHD based on clinical interviews. Venous blood was obtained from children and mice under aseptic conditions and the serum was centrifuged and preserved. Clear supernatants from mice and children were processed simultaneously in duplicate, side by side, for ELISA assay with the calibrators supplied in the GFAP and GAD65-Ab kit.

resultsIn mice with ADHD-like behaviors, there was a strong positive connection between serum GFAP levels and open-arm times in the elevated plus maze, which corresponded with the association between serum GFAP levels and hyperactivity-impulsivity ratings (r [Spearman] = 0.496, P = 0.004). The optimal cut-off value of serum GFAP levels as an indicator for auxiliary diagnosis of ADHD was projected to be 28.8 ng/ml based on the receiver operating characteristic (ROC) curve, yielding a sensitivity of 28.6% and a specificity of 100%; the area under the curve was 0.7221 (95% CI, 0.5553–0.8889; P = 0.0214). Additionally, we discovered that in mice exhibiting ADHD-like behaviors, a reduction in context-related freezing time was connected to an increase in blood GAD65-Ab levels. With an ideal cut-off value of 9.2 ng/ml (sensitivity, 77.3%; specificity, 88.4%; Area Under the Curve (AUC), 0.7044; 95%CI, 0.5336–0.8752; P = 0.0342), there was a striking link between inattention scores and serum GAD65-Ab levels (P = 0.0336; r [Pearson] = 0.486, P = 0.048).

conclusionThe data support the theory that elevated blood levels of GFAP and GAD65-Ab may be involved in the pathophysiology of ADHD in children and that these levels may be correlated with the severity of ADHD in children.

trial registrationName of the registry: The study of the accuracy and specificity of glial fibrillary acid protein (GFAP) combined with glutamate decarboxylase autoantibody GAD-Ab in the diagnosis of Attention Hyperactivity Deficit Hyperactivity Disorder (ADHD). Trial registration number: ChiCTR2300068366. Date of registration: 02/16/2023. URL of trial registry record: https://www.chictr.org.cn/index.html .

Indexed as

Attention Deficit Disorder with HyperactivityAutoantibodiesGlial Fibrillary Acidic ProteinGlutamate DecarboxylaseAnimalsBiomarkersChildDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiceROC CurveAutoantibodiesBiomarkersGlial Fibrillary Acidic ProteinGlutamate Decarboxylaseglutamate decarboxylase 2Attention deficit hyperactivity disorderGAD65-AbGFAPHyperactivity-impulsivityInattention

Identifiers

PMID41864973
PMCPMC13130535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.